Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
News about Skye Bioscience Inc
Skye Bioscience: Navigating the Road Ahead with Phase 2 Data and Market Challenges
Jan 13 2025
Skye Bioscience Inc., a trailblazer in the innovative realm of cannabinoid-based therapeutics, is gearing up for a significant year in 2025. As the co...
Skye Bioscience Reaches Milestone in Innovative Obesity Treatment as Market Landscape Evolves
Nov 14 2024
In an impressive leap towards addressing the growing global obesity epidemic, Skye Bioscience, Inc. (Nasdaq: SKYE) has announced that it has surpassed...
Skye Bioscience: Navigating Financial Struggles While Pioneering a Revolution in Metabolic Health Through Nimacimabs Groundbreaking CB1 Inhibition,
Nov 04 2024
Skye Bioscience Inc., a clinical-stage biopharmaceutical company based in San Diego, has recently made...
In an era of rapid advancements and transformative breakthroughs, Skye Bioscience, Inc. stands at the nexus...
Nov 01 2024
Unlocking Potential Amidst Challenges: Skye Bioscience to Share Third Quarter 2024 Results In an era of rapid advancements and transformative breakthr...
A Glimmer of Hope in the Labyrinth of Loss The Promising Pursuits of Skye Bioscience
Sep 23 2024
In the grand tapestry of medical advancement, where the delicate threads of hope and despair often intertwine, the esteemed Skye Bioscience Inc. emerg...
Skye Bioscience Appoints Dr. Puneet S. Arora as CMO to Navigate Financial Turbulence and Pave the Way for Metabolic Health Breakthroughs,
Sep 03 2024
By City, - Skye Bioscience, a clinical-stage biopharmaceutical company dedicated to uncovering innovative therapeutic avenues for metabolic...
Skye Bioscience Grants Non-Qualified Stock Options to New Employee, Demonstrating Commitment to Unlocking Therapeutic Pathways for Metabolic Health
Aug 23 2024
SAN DIEGO, Aug. 23, 2024 - Skye Bioscience, a clinical-stage biopharmaceutical company specializing in discovering innovative therapeutic pa...
Skye Bioscience Embarks on Groundbreaking Phase 2 Trial to Tackle Obesity with Nimacimab
Aug 22 2024
In an exciting development in the field of obesity treatment, Skye Bioscience has announced the launch of its Phase 2 clinical trial, known as the CBe...
Skye Bioscience Reveals Phase 2 Nimacimab Trial with Focus on Metabolic Rewiring and Sleep Apnea in Collabo...
Jul 24 2024
In a compelling virtual Key Opinion Leader (KOL) event, Skye Bioscience recently unveiled comprehensive insights into their innovative work on metabol...
Skye Bioscience Inc Analyzing the Under-Performance and Future Prospects
Jul 12 2024
In recent weeks, Skye Bioscience Inc s shares have shown a significant under-performance compared to the overall market. This article aims to examine ...
Skye Bioscience Inc Faces Concerns as Operating Loss Declared in Third Quarter of 2023
Nov 17 2023
The recent financial reports from Skye Bioscience Inc have not been promising, causing concern among stockholders. During the July to September 30th r...
Skye Bioscience Inc reports staggering operating shortfall of $-3.1 million in Q1 2023 earnings, sparking investor concern
May 14 2023
In the latest news from the major pharmaceutical preparations sector, industry veterans are still analyzing the first quarter performance of 2023. One...